Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Shanzay M. Khan"'
Autor:
Ashley D. Hadjis, Natalia S. Nunes, Shanzay M. Khan, Rochelle E. Fletcher, Alessandra de Paula Pohl, David J. Venzon, Michael A. Eckhaus, Christopher G. Kanakry
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
Post-transplantation cyclophosphamide (PTCy) reduces the incidence and severity of graft-versus-host disease (GVHD), thereby improving the safety and accessibility of allogeneic hematopoietic cell transplantation (HCT). We have shown that PTCy works
Externí odkaz:
https://doaj.org/article/2353e45dfe2c40c589b13c56dc2a4754
Autor:
Rochelle E. Fletcher, Natalia S. Nunes, Michael T. Patterson, Natasha Vinod, Shanzay M. Khan, Suresh K. Mendu, Xianghong Li, Alessandra de Paula Pohl, Lucas P. Wachsmuth, Hyoyoung Choo-Wosoba, Michael A. Eckhaus, David J. Venzon, Christopher G. Kanakry
Publikováno v:
Blood Adv
Posttransplantation cyclophosphamide (PTCy), given on days +3 and +4, reduces graft-versus-host disease (GVHD) after allogeneic hematopoietic cell transplantation (HCT), but its immunologic underpinnings are not fully understood. In a T-cell–replet
Autor:
Michael T. Patterson, Shanzay M. Khan, Natalia S. Nunes, Rochelle E. Fletcher, Jing Bian, Ashley D. Hadjis, Michael A. Eckhaus, Suresh K. Mendu, Alessandra de Paula Pohl, David J. Venzon, Hyoyoung Choo-Wosoba, Kazusa Ishii, Haiying Qin, Terry J. Fry, Maggie Cam, Christopher G. Kanakry
Publikováno v:
Blood. 141:659-672
Relapse limits the therapeutic efficacy both of chimeric antigen receptor (CAR) T cells and allogeneic hematopoietic cell transplantation (allo-HCT). Patients may undergo these therapies sequentially to prevent or treat relapsed malignancy. However,
Autor:
Michael T. Patterson, Natalia S. Nunes, Lucas P. Wachsmuth, Amrit Panjabi, Rochelle E. Fletcher, Shanzay M. Khan, Dimana Dimitrova, Jennifer A. Kanakry, Leo Luznik, Christopher G. Kanakry
Publikováno v:
Blood advances. 6(17)
Mechanisms of T-cell survival after cytotoxic chemotherapy, including posttransplantation cyclophosphamide (PTCy), are not well understood. Here, we explored the impact of PTCy on human CD8+ T-cell survival and reconstitution, including what cellular
Autor:
Ashley D, Hadjis, Natalia S, Nunes, Shanzay M, Khan, Rochelle E, Fletcher, Alessandra de Paula, Pohl, David J, Venzon, Michael A, Eckhaus, Christopher G, Kanakry
Publikováno v:
Frontiers in immunology. 13
Post-transplantation cyclophosphamide (PTCy) reduces the incidence and severity of graft-versus-host disease (GVHD), thereby improving the safety and accessibility of allogeneic hematopoietic cell transplantation (HCT). We have shown that PTCy works
Autor:
Christopher G. Kanakry, David Venzon, Natalia S. Nunes, Rochelle Fletcher, Michael Eckhaus, Michael T. Patterson, Suresh K. Mendu, Lucas P. Wachsmuth, Shanzay M. Khan
Publikováno v:
Biology of Blood and Marrow Transplantation. 26:S169-S170
The use of PTCy substantially lowers the rates of severe acute and chronic graft-versus-host disease (GVHD) after allogeneic hematopoietic cell transplantation (HCT), but the mechanisms of its action are incompletely understood. Recently, we showed i